Endovascular Aortic Repair in Nonagenarian Patients

Prendes, Carlota F.; Dayama, Anand; Panneton, Jean M.; Stana, Jan; Rantner, Barbara; Alvarez Marcos, Francisco; Mani, Kevin; Wanhainen, Anders und Tsilimparis, Nikolaos (2021): Endovascular Aortic Repair in Nonagenarian Patients. In: Journal of the American College of Cardiology, Bd. 77, Nr. 15: S. 1891-1899

Abstract

BACKGROUND The increasing proportion of elderly patients being treated for abdominal aortic aneurysm (AAA) in the endovascular era is controversial. OBJECTIVES This study compared 30-day outcomes of endovascular aortic repair (EVAR) in nonagenarians (NAs) with non-nonagenarians (NNAs). METHODS This retrospective analysis of the American College of Surgeons National Surgical Quality Improvement Program database included EVAR procedures performed from 2011 to 2017. Multivariate logistic regression in the unadjusted cohort, followed by propensity-score matching (PSM), was performed. Primary outcomes were 30-day mortality and 30-day major adverse events. RESULTS A total of 12,267 patients were included (365 NAs). Ruptured aneurysms accounted for 6.7% (n = 819): 15.7% (n = 57) in NAs versus 6.5% (n = 762) in NNAs (p < 0.001). Mean aneurysm diameter was 6.5 +/- 1.8 cm in NAs versus 5.8 +/- 1.7 cm in NNAs (p < 0.001). The unadjusted 30-day mortality was 9.9% in NA versus 2.2% in NNAs (p < 0.001). Multivariate analysis revealed age $90 years (odds ratio [OR]: 3.36), male sex (OR: 1.78), functional status (OR: 4.22), pre-operative ventilator dependency (OR: 3.80), bleeding disorders (OR: 1.52), dialysis (OR: 2.56), and ruptured aneurysms (OR: 17.21) as independent predictors of mortality. After PSM, no differences in 30-day mortality (intact AAA [iAAA]: 5.3% NA vs. 3% NNA [p = 0.15];ruptured AAA [rAAA]: 38% NA vs. 28.6% NNA [p = 0.32]) or 30-day major adverse events (iAAA: 7% NA vs. 4.6% NNA [p = 0.22];rAAA: 28% NA vs. 36.7% NNA [p = 0.35]) were observed. CONCLUSIONS Age was identified as an independent predictor of 30-day mortality after EVAR on multivariate analysis. However, no differences were found after PSM, suggesting that being $90 years of age but with similar comorbidities to younger patients is not associated with a higher short-term mortality after EVAR. Age $90 years alone should not exclude patients from EVAR, and tailored indications and carefully balanced risk assessment are advised. (J Am Coll Cardiol 2021;77:1891-9) (c) 2021 by the American College of Cardiology Foundation.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0735-1097
• Sprache: Englisch